Our Company

DEHA is a preclinical stage pharmaceutical company founded in 2015. The company focuses on developing best-in-class therapies for the treatment of edema related disorders of unmet medical need in patients with large stroke, TBI and several other CNS injuries.

 

Target/Technology:

Innovative compounds targeting key driver of edema in several indications. Our discovery efforts have yielded multiple potent water channel inhibitors. These compounds have the opportunity to treat edema-related disorders. DEHA plans to move forward in its development by requesting FDA Fast-track development status and Orphan designation.